Kezar Life Sciences (NASDAQ: KZR)
Kezar Life Sciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kezar Life Sciences Company Info
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
News & Analysis
Why Kezar Life Sciences Stock Is Crushing It Today
A positive phase 2 data readout is lighting a fire underneath the biotech's shares today.
Why Kezar Life Sciences Stock Is Soaring Today
The company reported promising results from a phase 2 study.
Why Kezar Life Sciences Is Down Today
The company's public offering of common stock doesn't exactly thrill investors.
Is This Flaming Hot Biotech Stock a Buy?
Kezar Life Sciences just released interim results on its only drug and shares jumped 70%. Now that the stock has settled, is it a good time to buy?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.